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Cyclin-Dependent Kinase 1 (CDK1) is the major M-phase kinase known also as the M-phase Promoting Factor or MPF. Studies
performed during the last decade have shown many details of how CDK1 is regulated and also how it regulates the cell cycle
progression. Xenopus laevis cell-free extracts were widely used to elucidate the details and to obtain a global view of the role
of CDK1 in M-phase control. CDK1 inactivation upon M-phase exit is a primordial process leading to the M-phase/interphase
transition during the cell cycle. Here we discuss two closely related aspects of CDK1 regulation in Xenopus laevis cell-free extracts:
ﬁrstly, how CDK1 becomes inactivated and secondly, how other actors, like kinases and phosphatases network and/or speciﬁc
inhibitors, cooperate with CDK1 inactivation to assure timely exit from the M-phase.
1.Introduction
The cell cycle regulation comprises a network of numerous
kinases and phosphatases. CDK1 is a major kinase necessary
bothfortheS-phaseandM-phaseprogression.Identiﬁcation
at the end of XX century of the CDK1 as a major regulator of
the cell cycle made the understanding of its own regulation a
fascinating topic. The use of Xenopus laevis cell-free extracts
has had a large impact on these studies.
CDK1belongstothefamilyofCyclin-DependentKinases
(CDKs). It has been the ﬁrst CDK described in yeast (as
ap r o d u c to fcdc2 or cdc28 gene depending on species)
and human (called p34cdc2) .T h en a m eo fC D K sc o m e s
from the association of these kinases with the regulatory
subunits called cyclins. Similarly to all other kinases CDK1
hasinitsamino-terminaldomainanxGxPxxxxRExsequence
(where x represents any amino acid). This conserved region
corresponds to a cyclin-binding domain [1]. There are
twenty-one CDK-coding genes in the human genome [2].
However, only a few of them are involved in cell cycle
regulation. In Xenopus laevis oocytes and early embryos
a handful of CDKs are expressed (CDK1, CDK2, CDK5,
CDK9; our unpublished data). Two major CDKs taking part
in cell cycle regulation are CDK1 and CDK2. Only CDK1
seems to be involved in M-phase regulation, while CDK2
is a major player in S-phase progression. The similarity in
three-dimensional structure of these two kinases helps to
understand some aspects of their regulation.
CDK1 activity picks only for a very short period of time
upon G2/M transition and falls down rapidly at the M-phase
exit. The structure of CDK1 is bilobate, similar to the cyclic
AMP-dependent protein kinase, but contains a unique helix-
loop segment that interferes with ATP and protein substrate
binding. In its monomeric inactive form, CDK1 binds to the
ATP in a conformation, which prevents a nucleophilic attack
by hydroxyl substrate on the β-γ phosphate bridge of ATP
[3].
Cyclins, the regulatory subunits of CDKs, are encoded
by at least 15 diﬀerent genes in human genome [2]. Only
some of them are expressed in oocytes and early embryos of
Xenopus laevis. B-type cyclins are main regulators of CDK1.
In Xenopus laevis early developmental stages ﬁve of B-type2 Enzyme Research
cyclins (B1–B5) were identiﬁed [4]. B1 and B2 cyclins play a
majorroleinM-phaseregulationinXenopus laevis sincethey
are associated with the majority of CDK1s. Upon M-phase
exit cyclins are degraded sequentially beginning from cyclin
B1 and ending with cyclin B5. This sequential degradation
of cyclins reﬂects inactivation of successive parts of CDK1.
Thus just a brief look at the composition and metabolism
of CDK1/cyclin B complexes illustrates the complexity of the
system, and this is just the tip of the iceberg.
2. M-Phase Control inXenopus laevis Oocytes
viaMPF, CSF,andCalciumSignalling
Amphibian oocytes have been excellent model system
allowing the discovery of the basic principles of M-phase
regulation. Most of the molecules regulating M-phase entry,
maintaining, and exit were identiﬁed with the help of the
amphibian experimental model. The enzymatic complex of
CDK1 and cyclin B is the universal regulator of the M-
phase. It was ﬁrst discovered as an activity called Maturation
Promoting Factor (MPF) by Masui and Markert in 1971
[5]. MPF drives both meiotic and mitotic cell cycle via
M-phase entry induction. Masui and Markert discovered
the MPF activity in experiments involving a cytoplasmic
transfer between mature and immature oocytes of Rana
pipiensandXenopus laevis.Suchatransferinvariablyinduced
resumption of meiotic maturation, that is, M-phase entry
in G2-arrested immature oocytes. Initially, the MPF activity
was called a Maturation Promoting Factor because of its
ability to induce maturation upon injection into immature
oocytes. However further studies have shown that the very
samefactorinducesalsothemitoticM-phase.Thusthename
of Maturation Promoting Factor was changed to M-phase
Promoting Factor. Soon after, the MPF was shown to have
an M-phase-inducing activity regardless of the species. This
suggested the key role of this molecule in the induction
of the M-phase of cell cycle in all eukaryotic cells. After
numerouseﬀorts,MPFwasidentiﬁedasacomplexofCyclin-
Dependent Kinase 1 (CDK1) and its regulatory subunit
cyclin B [6–9].
Masui and Markert [5] demonstrated the presence of
another factor that stabilized MPF in MII-arrested oocytes.
They called it the CSF for CytoStatic Factor. Identiﬁcation
of the molecular identity of CSF took more time and
energy than identiﬁcation of MPF. The key player in the
CSF pathway was discovered recently as a protein called
Early mitotic inhibitor 2 (Emi2) [10–13]. Emi2 arrests
the Ubiquitin/Proteasome System (UPS) by an inhibitory
association with APC/CCdc20 ubiquitin ligase necessary for
cyclin B ubiquitination and targeting the CDK1/cyclin B to
proteasomes where cyclin B becomes degraded. Thus, CSF
holds APC/C in an inactive state assuring MII arrest in
oocytes, and Emi2 is the most downstream eﬀector.
Amphibian oocytes, similarly to the majority of other
vertebrate oocytes, are ovulated in MII-arrested state. Mos/
.../ERK2 MAP kinase pathway stabilizes Emi2 during this
period. The stabilization of Emi2 is achieved via phos-
phorylation on Thr 336, Ser 342, and Ser 344 by the
most downstream enzyme of ERK2 MAP kinase pathway,
the Rsk90 kinase. These phosphorylations promote Emi2-
PP2AinteractionandthusantagonizeEmi2phosphorylation
by CDK1/cyclin B [14]. Other residues, namely T545 and
T551, are phosphorylated by CDK1/cyclin B [15]. These
phosphorylations are removed by protein phosphatase 2A
(PP2A) assuring the turnover of Emi2 phosphorylation
during the oocyte MII arrest (Figure 1).
Uponfertilization,thespermatozoonenteringtheoocyte
induces a burst of free calcium in the ooplasm. The
calcium signaling plays a major role in triggering the
developmental program of the embryo. The rapid increase
in calcium concentration inactivates CSF. The ﬁrst step is
activation of calcium-dependent kinase 2 (CaMK2), which
phosphorylates Emi2. This turns Emi2 into a substrate for
Plk1, the kinase which is already active in MII oocytes
before fertilization, but unable to phosphorylate Emi2 before
it becomes modiﬁed by CaMK2 (Figure 1). The double
CaMK2- and Plk1-mediated modiﬁcation of Emi2 following
fertilization makes this protein recognizable by SCFβ-TRCP
ubiquitin ligase. SCFβ-TRCP triggers Emi2 polyubiquitination
followed by its proteasome-dependent degradation and
disappearance from the ooplasm. This complex process is
necessary to remove the CSF activity and to release the MII
arrest of oocytes upon fertilization via APC/C activation and
triggering cyclin B polyubiquitination [10–12].
Despite the major role of the Mos/.../ERK2 MAP kinase
pathway resulting in Emi2 stability other alternative CSF
pathways seem also involved in MII arrest induction and
maintenance. For example, CDK2/cyclin E pathway was
shown to induce a CSF-like arrest in Xenopus laevis cell-
free extracts [16]. A checkpoint kinase Mps1 (Monopolar
spindle 1) is necessary for this action of CDK2/cyclin E [16].
Further details of the role of this alternative CSF pathway
and especially its elimination upon oocyte activation remain
unknown.
The CSF inactivation is not the only eﬀect of the rise in
calcium concentration upon fertilization. The calcium burst
also triggers a transient activation of a phosphatase called
calcineurin [17, 18], which is absolutely necessary for oocyte
activation. However, it is unknown whether calcineurin acts
on CDK1 or on some of its substrates. Nevertheless, these
results pinpoint the network of kinases and phosphatases
involved in phosphorylation and dephosphorylation events
ofnumerousproteins asmajormeantoregulatethecellcycle
transition necessary to initiate the embryo development.
3.CDK1Inactivationwithout
Cyclin B Degradation
Proteolytic degradation of cyclin B via UPS plays a major
role in cell cycle regulation. Its perturbation disorganizes the
cell cycle progression [19–21]. Inhibition of the proteolytic
activity of proteasome with inhibitors like MG115, MG132,
or ALLN arrests cells in M-phase with high cyclin B content
and equally high CDK1 activity. The same inhibitors block
also cyclin B degradation in Xenopus laevis cell-free extracts;
however, they neither arrest CDK1 inactivation nor provoke
the M-phase arrest [22–24]. This important diﬀerence
between the reaction of intact cells and cell-free extractsEnzyme Research 3
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Figure 1: Regulation of Emi2 association with APC/CCdc20. Phosphorylation sites in theupper part of Emi2 are inhibitoryfor the association
and are protected during MII arrest (green arrows and symbols of inhibition), while the sites in the bottom part of Emi2 are activatory for
the association and the CSF-arrest exit (red arrows).
strongly suggests that CDK1 inactivation proceeds without
cyclin B degradation at least in Xenopus laevis oocytes and
embryo extracts. The reason for such a diﬀerent reaction
of intact cells and cell-free extract to proteasome inhibition
remains unclear. It seems reasonable to speculate that in the
case of somatic cells some upstream substrate of proteasome
pathway must be degraded before cyclin B could be targeted
for degradation. In this case the proteosome inhibition
would inhibit cyclin B degradation indirectly, via action
of remaining upstream substrate of UPS. However, the
identity of a potential UPS substrate conditioning cyclin B
degradation in intact cells remains unknown.
The ﬁrst step in cyclin B degradation is its polyubiqui-
tination by APC/C ubiquitin ligase (Figure 2). This process
takes place when cyclin B is still associated with CDK1. Thus,
APC/C-mediated polyubiquitination targets the proteasome
not only cyclin B but the whole complex, which is still
active when cyclin B is in the polyubiquitinated state. The
proteasome induces or catalyses the dissociation of cyclin B
from its CDK1 partner. Nishiyama and colleagues [22]h a v e
shown that the activity of the 26S proteasome involved in
cyclin B dissociation from CDK1 is associated with its 19S
regulatory subunit. It seems that the lid of the proteasome
couldbeinvolvedinthisprocess.The19Ssubunitsofprotea-
some may also deubiquitinate and concomitantly denature
cyclin B before it becomes loaded into the 20S proteasome
catalytic chamber. This hypothetical modiﬁcation of cyclin
B may, as a side eﬀect, trigger its dissociation from CDK1.
Takeo Kishimoto’s group named the dissociating activity of
the proteasome a “nonproteolytic activity” to distinguish it
from the classical proteolytic activity [22].
The APC/C activity is itself positively regulated in large
part by CDK1/cyclin B-dependent phosphorylations of its
numerous subunits [25, 26]. These phosphorylations trigger
cyclin B polyubiquitination, dissociation from CDK1, and
degradation resulting in CDK1 inactivation. In addition,
the substrate speciﬁcity of APC/C changes during mitosis,
due to the switch in its regulatory subunit, from Cdc20
(Fizzy) to Cdh1 (Fizzy related). This switch is possible after
Cdc20 polyubiquitination by APC/C and its subsequent
degradation. Thus, CDK1/cyclin B indirectly regulates itself
via controlling APC/C activity at least at two diﬀerent levels,
which in turn determines the stability of cyclin B (reviewed
in [27, 28]).
4.CDK1InactivationIsInhibited
by Interference with Cyclin B
Polyubiquitination
Ubiquitinisahighlyevolutionaryconservedsmall(76amino
acids) polypeptide. Its COOH terminus is covalently linked
to lysine residues of a substrate (e.g., cyclin B) via an
isopeptide bond (for a review see [29]). Polyubiquitination
proceedsviamultipleroundsofubiquitinationduringwhich
the COOH terminus of a new ubiquitin molecule forms

















































Figure 2: Canonical pathway of CDK1/cyclin B inhibition.
previously attachedto thesubstrate. This process is mediated
by three sequentially acting enzymes (E1, E2 and E3, the last
being an ubiquitin ligase). Lysine 48 of ubiquitin molecule
is one of the major residues involved in polyubiquitination,
mediating subsequent targeting of substrates to the protea-
some. However, all seven lysine residues present within the
molecule of ubiquitin are able to form isopeptide bonds
[29–31]. A mutation of lysine 48 (K48) to arginine (R)
severely aﬀects the process of polyubiquitination [32, 33].
Such ubiquitin mutant (UbiK48R) was used to perturb
ubiquitination of proteins during the M-phase in the cell-
free mitotic extracts upstream from the inhibition of the
proteolytic activity of the proteasome. The interference with
the polyubiquitination pathway via UbiK48R arrests cyclin B
dissociation from CDK1 and its degradation [34]. Therefore,
the polyubiquitination pathway appears to be necessary for
the targeting of cyclin B complexed with CDK1 to the
proteasome. This in turn results in the maintenance of high
activity of CDK1 and keeping the extract in the M-phase.
Thus UPS inhibition at the level of polyubiquitination and
not at the level of the proteasome proteolytic activity inhibits
eﬀectively CDK1 inactivation. This points to the importance
of cyclin B dissociation from CDK1 and not the degradation
of cyclin B.
5.AlternativePathwaystoInactivateCDK1
5.1. Dephosphorylation of CDK1 Threonine 161. The phos-
phorylation of threonine 161 residue of CDK1 is necessary
for activation of CDK1. Thus, the dephosphorylation of
this site may inactivate CDK1 independently of cyclin B
dissociation and proteolysis [35,36].The dephosphorylation
is catalyzed by the okadaic-acid-(OA-)sensitive type 2C
protein phosphatases (PP2Cs) [36]. The comparison of
the dynamics of CDK1 inactivation with the dynamics of
CDK1 Thr161 dephosphorylation upon M-phase exit has
shown that the latter follows CDK1 inactivation [24]. The
detailed analysis of the interaction between CDK1 and cyclin
B2 (one of ﬁve cyclins B potentially present in Xenopus
laevis early embryos) upon M-phase exit revealed that the
dissociation of cyclin B2 from CDK1 perfectly correlates
with the dynamics of CDK1 inactivation and not with
CDK1 threonine 161 dephosphorylation [24]. Thus, CDK1
threonine 161 residue dephosphorylation is a relatively late
step in CDK1 inactivation and perhaps plays a role in the
ultimate switching oﬀ of the CDK1, thus protecting the
cell against unscheduled and premature reactivation of the
kinase after the M-phase exit.
5.2. Transient Inhibitory Phosphorylation of CDK1 on Thre-
onine 14 and Tyrosine 15. As t u d yi nXenopus laevis cell-free
extractshasshownthatatransientphosphorylationofCDK1
on tyrosine 15 (and most probably on threonine 14) could
also participate in CDK1 inactivation. D’Angiolella and
colleagues have shown that in cycling cell-free extracts the
cyclin B1-associated histone H1 kinase activity diminishes
more rapidly than the level of cyclin B1 protein [37].
This was not the case for cyclin A-associated activity and
the diminution of the level of cyclin A protein. Detailed
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Figure 3: Hypothesis of alternative pathways involvement during CDK1/cyclin B dissociation.
meiosis (CSF extract treated with calcium) has revealed a
transient rephosphorylation of cyclin B-associated CDK1 on
tyrosine 15 following the initial drop in CDK1 inactivation.
This short-lasting increase in tyrosine 15 phosphorylation
could be mediated by a transient increase in association
of CDK1 with Wee1 kinase catalysing the reaction of
phosphorylation at this site. However, another study has
shownthatCDK1dephosphorylationattyrosine15precedes
thekinase inactivation [38] (Figure3). Thus, itis not entirely
clear to what extend this kind of regulation inﬂuences the
dynamics of CDK1 inactivation.
5.3. Speciﬁc Inhibitors May Participate in CDK1 Inactivation.
Data from yeast and HeLa cells suggest that the speciﬁc
inhibitors could also be involved in CDK1 inactivation upon
mitotic exit. Cdc6 protein, well known as a key S-phase
regulator, could play this role [39, 40] (Figure 3) .T h e r ei sn o
data supporting such a role of Cdc6 in Xenopus laevis cells.
However, since Cdc6 was shown to inhibit CDK1 both in
yeast and in human cells it seems possible that it also plays
the same role in amphibians. CDK1 inhibition speciﬁcally
duringtheM-phaseexitmaylead,togetherwiththetransient
CDK1 phosphorylation on tyrosine 15, to more rapid and
more eﬀective inhibition of CDK1.
5.4. Cooperation of CDK2 and PKA in CDK1 Inactivation.
The next alternative pathway of CDK1/cyclin B inactivation
implies the participation of CDK2. It was shown that
CDK2/cyclin E enables to maintain the high CDK1/cyclin
B activity during mitosis in Xenopus laevis cell-free extract
[41]. Premature inactivation of CDK2 during the mitotic M-
phase induces an increase in protein kinase A (PKA) activity
and speeds up CDK1/cyclin B inactivation and cyclin B
degradation. Thus, CDK2/cyclin E seems to be coupled with
PKA activity in assuring a correct timing of CDK1/cyclin
B inactivation and the M-phase exit. However, it remains
unknown how CDK2 and PKA act in concert on CDK1 and
cyclin B degradation pathway.
Crystallographic studies of another CDK2 enzymatic
complex, namely, CDK2/cyclin A that has fundamental role
in S-phase regulation, have shown details of the mechanism
underlying inactivation of this kinase [2, 42]. CDK1/cyclin
B complex has never been studied with such accuracy.
As the two complexes are closely related the mechanism
proposed for CDK2 may also apply to CDK1. The active
site of CDK1 could undergo conformational changes in its
PSTAIRE helix and T-loop upon the dissociation of cyclin
B, as it happens with CDK2 upon dissociation of cyclin A.
Such a conformational change prevents proper interaction
of the enzyme with ATP and inactivates the kinase [2,
42]. The cyclin subunit determines substrate speciﬁcity of
CDKs (reviewed in [43]). Thus, the loss of cyclin subunit
should be immediately followed by eﬃcient inactivation of
CDK1 to protect the cell against possible phosphorylation of
undesired substrates. A part of this job may be performed
by the transient inhibitory phosphorylation of tyrosine 15.
Another possibility to eliminate unspeciﬁc activity of cyclin-
free CDK1 would be a direct inhibition via its association
with a speciﬁc inhibitor, for instance, Cdc6.
6. Kinase/Phosphatase Networkupon
M-Phase Exit
In HeLa cells CDK1 inactivation is not suﬃcient to assure
the successful transition to interphase. The eﬃcient tran-
sition to interphase requires a phosphatase activity (or
activities) dephosphorylating CDK1 mitotic substrates [44].
The activation of these phosphatases is clearly proteasome-
dependent, but independent of cyclin B degradation. PP2A
was shown to be the major phosphatase dephosphorylating
CDK1 substrates in interphase Xenopus laevis eggs extract
[45]. PP2A is a heterotrimer composed of the catalytic C-,6 Enzyme Research
scaﬀolding A-, and regulatory B-type subunits represented
bydiﬀerentisoforms.TheB-typesubunitsareresponsiblefor
the substrate speciﬁcity of the whole complex [46]. Mochida
and colleagues [45] have shown that PP2A containing the
B55δ subunit is the major phosphatase controlling the
exit from the M-phase via dephosphorylation of CDK1
phospho-substrates. It was proposed that the newly discov-
ered Greatwall kinase could play a role of a phosphatase
suppressor [47]. Greatwall kinase was discovered in a
screen for Drosophila mutants defective in chromosome
condensation [48]. Greatwall is a ubiquitous evolutionarily
conserved protein kinase, known in humans as MAST-L
kinase, belonging to the AGC family of Ser/Thr kinases [49].
Depletion of this kinase from M-phase extracts induced
activation of an okadaic-sensitive phosphatase that acts on
CDK1 substrates and on the mitotic exit. Addition of this
kinase to interphase extracts inhibited dephosphorylation
of CDK1 substrates [50, 51]. Moreover, the inability of
Greatwall-depleted cell-free extracts to enter M-phase was
reverted by removal of PP2A-B55 delta [50]. It was shown
recently by two independent laboratories that a small protein
called cAMP-regulated phosphoprotein-19 (ARPP-19), a
close relative of another small protein alpha-endosulﬁne
(ENSA), was an ideal substrate for Greatwall kinase in
Xenopus laevis cell-free extracts [52, 53]. Thus, the network
of kinases and phosphatases governing CDK1 substrates
dephosphorylation, and thus, the transition to interphase
following the M-phase was discovered.
7. Conclusions
Several pathways control CDK1 inhibition upon M-phase
exit. The major pathway called here canonical involves
dissociation of cyclin B from CDK1 and is followed by
cyclin B degradation and disappearance from the cell. Other
probably minor pathways, including phosphorylation and
dephosphorylation of CDK1 at diﬀerent sites, and active
inhibition of CDK1 kinase activity, may play supplementary
role in shortening the process of CDK1 inactivation. This
hypothetical role of CDK1 accelerator could be of particular
importanc eforv eryfastclea vingembry ossuchasamphibian
embryos. CDK2/cyclin E and PKA seem also to exercise
an important control over the timing of CDK1/cyclin B
inactivation. The alternative pathways in CDK1/cyclin B
inactivation may be important in certain unique conditions
when the canonical pathway becomes ineﬀective. For exam-
ple, in rat one-cell embryos treated with MG132 the M-
phase exit probably occurs without cyclin B degradation
[54]. Also in mouse oocytes undergoing maturation and
fertilized in vitro by numerous spermatozoids CDK1/cyclin
B is inactivated rather via threonine 161 dephosphorylation
than full cyclin B degradation [55]. Surprisingly, recent
studies of the minimal control of CDK network in ﬁssion
yeast suggest that modulation of CDK1 activity and not its
proteolytic or phosphorylation-dependent regulation could
play an ancestral role during evolution [56]. This discovery
will certainly stimulate further studies on noncanonical
pathways regulating M-phase exit, and it is possible that the
canonical pathway will become noncanonical and vice versa.
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